Barclays analyst Balaji Prasad raised the firm’s price target on Teva (TEVA) to $28 from $25 and keeps an Overweight rating on the shares. The firm says Duvakitug with a 27% delta clinical remission for ulcerative colitis and 35% delta endoscopic response for Crohn’s disease reflects a best in class efficacy profile. The data further validate Teva’s pivot to growth strategy, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TEVA:
- TD says Spyre has ‘superior TL1A program’ after Teva data
- Teva and Sanofi (SNY) Jump amid Impressive Drug Results
- Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG
- Teva price target raised to $25 from $23 at BofA
- Teva rises 21.4%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
